Albert D M, Niffenegger A S, Willson J K
David G. Cogan Eye Pathology Laboratory, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston.
Surv Ophthalmol. 1992 May-Jun;36(6):429-38. doi: 10.1016/s0039-6257(05)80024-4.
This article reviews the published clinical responses of metastatic uveal melanoma and metastatic cutaneous melanoma with visceral involvement to current therapeutic protocols. Despite isolated patient responses to systemic treatment, no effective treatment currently exists for metastatic uveal melanoma. However, several new approaches involving interferons and interleukin and combination chemotherapy have shown some activity against metastatic cutaneous melanoma. The effectiveness against metastatic uveal melanomas has not been determined. A new approach to intrahepatic administration of chemotherapy also warrants further evaluation because of the high incidence of hepatic involvement with metastatic uveal melanoma. When an effective systemic treatment is found, early administration as an adjuvant to primary treatment may provide the best strategy for control of systemic spread.
本文回顾了已发表的转移性葡萄膜黑色素瘤和伴有内脏受累的转移性皮肤黑色素瘤对当前治疗方案的临床反应。尽管有个别患者对全身治疗有反应,但目前尚无针对转移性葡萄膜黑色素瘤的有效治疗方法。然而,几种涉及干扰素、白细胞介素和联合化疗的新方法已显示出对转移性皮肤黑色素瘤有一定活性。其对转移性葡萄膜黑色素瘤的有效性尚未确定。由于转移性葡萄膜黑色素瘤肝转移的发生率很高,肝内化疗的新方法也值得进一步评估。当找到有效的全身治疗方法时,作为辅助治疗尽早给药可能是控制全身转移的最佳策略。